Zinger Key Points
- vTv has reduced the size of its Board of Directors from nine to seven members.
- vTv will use the proceeds to fund the first Phase 3 study of its lead product candidate, cadisegliatin, expected to start in mid-2024.
- Get Monthly Picks of Market's Fastest Movers
Wednesday, vTv Therapeutics Inc VTVT shares are soaring on a robust session volume of 2.7 million, compared to the average volume of 31.92 K as per the data from Benzinga Pro.
The company closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, and the JDRF T1D Fund, of 464,377 shares at $11.81 per share and pre-funded warrants for 3.85 million shares in lieu of vTv common stock in a private placement financing for total gross proceeds of $51 million.
Further, in conjunction with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members, three of whose members will be designated by the new investors, and includes Srinivas Akkaraju, MD, PhD, Founder and Managing General Partner at Samsara.
vTv will use the proceeds to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to be initiated in mid-2024.
vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small-molecule drug candidates.
vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for type 1 diabetes.
Price Action: VTVT shares are up 103.8% at $17.32 on the last check Wednesday.
Photo: Darko Stojanovic from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
